NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
- Funding
- Amount varies
- Deadline
- November 16, 2029
- Who can apply
- State governments, County governments, City or township governments +11 more
Description
The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The total duration of both R61 and R33 cannot exceed five years. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic of this program. A milestone is defined as a scheduled event in the project timeline that signifies the completion of a major project stage or activity. This program will support applications that propose a series of milestones including manufacturing and product development goals. Applications that address contingency plans to proactively confront potential delays in meeting the milestones are strongly encouraged. Milestones are required for both phases. Milestones must be specific, measurable, achievable, relevant, and time-bound (SMART). All projects will begin with a R61 phase regardless of therapeutic starting point.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled colleges and universities
- Federally recognized Native American tribal governments
- Public and Indian housing authorities
- Other Native American tribal organizations
- Nonprofits with 501(c)(3) status
- Nonprofits without 501(c)(3) status
- Private colleges and universities
- For-profit organizations (other than small businesses)
- Small businesses
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Industry Tags
About This Grant
The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The total duration of both R61 and R33 cannot exceed five years. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic of this program. A milestone is defined as a scheduled event in the project timeline that signifies the completion of a major project stage or activity. This program will support applications that propose a series of milestones including manufacturing and product development goals. Applications that address contingency plans to proactively confront potential delays in meeting the milestones are strongly encouraged. Milestones are required for both phases. Milestones must be specific, measurable, achievable, relevant, and time-bound (SMART). All projects will begin with a R61 phase regardless of therapeutic starting point.
Funding Information
Eligibility Overview
Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.
Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.
How to Apply
- 1
Review the full opportunity
Read the complete Notice of Funding Opportunity (NOFO) for this National Institutes of Health program on its official page (https://www.grants.gov/search-results-detail/360545).
- 2
Confirm eligibility
Check that your organization meets every requirement set by National Institutes of Health — applicant type, location, registration status, and any prior-award restrictions.
- 3
Prepare required documents
Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.
- 4
Submit before the deadline
This opportunity closes on November 16, 2029. Submit well before the deadline to leave time for fixes.
Grant Writing Tips
General tips for preparing your application:
- ✓Start early: registration and review steps take time.
- ✓Match your needs statement to the funder's stated priorities.
- ✓Have someone outside your team check the budget narrative.
More Grants from National Institutes of Health
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) →
- NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) →
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) →
- View all 356 grants from NIH →
Frequently Asked Questions
Who is eligible for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)?
Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.
How much funding does NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) provide?
An award amount is not stated in the listing for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed). See the official grant page for funding details.
When is the deadline for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)?
The application deadline for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) is November 16, 2029. Submit well before the deadline to leave time for fixes.
How do I apply for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)?
Apply for NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) through the official grant page (https://www.grants.gov/search-results-detail/360545). Confirm your eligibility and prepare your application materials before the deadline.
Helpful Resources
Need help writing your grant application?
Try Instrumentl — Grant Writing Software →Starting a nonprofit to apply for grants?
Launch your nonprofit with Swyft Filings →GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.